COYA News and Press, Coya Therapeutics Inc.

The study evaluated serum biomarkers of lipid peroxidation, systemic inflammation, and axonal integrity in 100 randomly selected patients with ALS and included 100 healthy controls to allow for a meaningful comparison Levels of 4-hydroxy-2-nonenal (4-HNE), lipopolysaccharide binding prote...

Howard Berman, Ph.D., the Company’s Founder and current Executive Chairman and Director, has stepped down from his roles, following the CEO transition process initiated in November 2024. Mark H. Pavao, a senior pharma and biotech executive, joins the Board as an independent directo...

Study results demonstrate significant reduction in regulatory T cell (Treg) function and significant increase in circulating pro-inflammatory cytokines and chemokines in patients with FTD Low-dose IL-2 plus CTLA-4 Ig has previously demonstrated restoration of regulatory T-cell function to...

Coya Therapeutics Inc. (COYA) is expected to report $-0.08 for Q4 2025

2026-03-16 08:14:43 ET More on Coya Therapeutics Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy's Seeking Alpha’s Quant Rating on Coya Therapeutics Historical earnings data for Coya Therapeutics Financial information for Coya The...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financ...

─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT ─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in neurological disorders Coya...

2026-01-30 08:47:22 ET More on Coya Therapeutics Seeking Alpha’s Quant Rating on Coya Therapeutics Historical earnings data for Coya Therapeutics Financial information for Coya Therapeutics Read the full article on Seeking Alpha For further det...

- Dr. Reddy’s Laboratories, Inc., a subsidiary of Coya’s current strategic collaborator, makes a $10 million investment - Greenlight Capital, Coya’s largest institutional shareholder, is the only other investor participating in the offering Coya Therapeuti...

Robust target engagement was observed, with statistically significant increases in regulatory T-cell (Treg) suppressive function and Treg numbers beginning as early as two weeks post-dosing and sustained through the 22-week treatment period. Cognitive measures remained stable, with no evidenc...